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Hemostasis and Biosurgicals in 
Trauma and Orthopedic Surgery
Saqeb Beig Mirza, Khaled Elawady, Syed Kashif Abbas, 
Shafat A. Gangoo and Sukhmeet S. Panesar
Abstract
Trauma and orthopedics is a specialty in which significant blood loss can be 
incurred both in terms of traumatic injuries and operative management. This 
chapter starts with a brief review of the biology of hemostasis followed by the 
importance of hemostasis in surgery. This is followed by a discussion on the ideal 
hemostatic agent. Various strategies of achieving hemostasis will be discussed 
including mechanical, thermal, pharmacological and topical agents in both elec-
tive orthopedic and spine surgery as well as in trauma. Specifically, we will look at 
synthetic agents such as cyanoacrylate, polyethylene glycol hydrogel and glutar-
aldehyde cross-linked albumin and absorbable agents such as gelatin foams and 
oxidized cellulose. We will also look at biological agents such as topical thrombin, 
sealants and platelet gels. Hemostatic dressings will be discussed in detail.
Keywords: hemostasis, coagulation, trauma
1. Introduction
There are a number of factors that influence patient outcome in trauma and 
orthopedic surgery in relation to hemorrhage. These can include patient factors, 
for example anticoagulant and antiplatelet medications, coagulopathies and other 
conditions, as well as surgical factors such as bony bleeding, large surgical incisions, 
diffuse venous bleeding and unseen sources of bleeding [1, 2].
Trauma still remains a leading worldwide cause of morbidity and mortality [3] 
and despite various developments over the years, hemorrhagic shock from trauma 
continues to form one part of the terrible triad contributing to mortality in both the 
military and civilian settings [4].
Effective hemostasis during surgery is advantageous to the surgeon as it prevents 
diffuse bleeding from capillaries and venules obscuring the surgical field and adding 
to operation time and infection risk [5, 6].
Significant blood loss has been associated with increased need for allogeneic 
and autologous blood transfusion [2, 7, 8]. These are associated with attendant risks 
including nosocomial infections [9], transfusion-related injury and fluid overload 
[10, 11]. In fact blood transfusion is an independent risk factor for infection, 
respiratory complications and the need for critical care support in traumatic injuries 
and resulted in a twofold increase in complications and critical care admissions, 
with more than two units of blood transfusion [7]. The risk of major periopera-
tive complications is also increased with high intraoperative blood loss [2, 12, 13]. 
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Therefore, patient outcome is optimal when the balance between bleeding and 
clotting is maintained during surgery such that tissue perfusion is adequate without 
excessive blood loss [5, 6].
2. The biology of hemostasis
Hemostasis in regard to trauma and surgery is a highly regulated process, main-
taining flow through vessels at the same time as the thrombotic response to tissue 
damage is occurring [14], thereby ensuring tissue perfusion and limiting blood loss. 
The process is a complex interaction between vascular endothelium, platelets, the 
coagulation and fibrinolytic systems [15, 16].
Following injury, a temporary vascular smooth muscle contraction occurs in 
an attempt to stem blood flow. Endothelial disruption exposes the subendothelial 
layer and circulating Von Willebrand factor attaches to the site of injury. Surface 
glycoproteins also adhere to platelet surfaces. The subendothelial collagen activates 
adhering platelets and their surface receptors then bind circulating fibrinogen, 
forming a soft platelet plug comprising aggregated platelets and fibrinogen [14]. 
The adhering platelets secrete humoral factors including serotonin, prostaglandins 
and thromboxane that maintain a reduced blood flow, creating an environment that 
is conducive to clot formation at the site of bleeding. At the same time, circulat-
ing coagulating factors produced by the liver are activated in a series of precisely 
controlled sequential and dependant reactions [14, 17].
The final common pathway is the activation of thrombin that leads to conversion 
of soluble plasma fibrinogen to insoluble fibrin. The complex of activated factor 
XIII and fibrin results in cross-linking of fibrin monomers to form a stable clot [17].
3. Techniques for hemostasis in trauma and orthopedic surgery
Broadly speaking, there are mechanical, thermal, pharmacological and topical 
methods of hemorrhage control [2, 6, 8, 17–20].
Mechanical methods include direct pressure, ligating clips and staples, sutures, 
fabric pads and gauze while hemostatic scalpels and lasers also reduce bleeding dur-
ing surgery [6, 7, 17]. However, these methods have their drawbacks with respect to 
certain situations. The location of bleeding is particularly important with respect to 
orthopedics and in particular trauma. Bony surface bleeding and bleeding from the 
intramedullary canals are almost impossible to control with mechanical methods. 
Inflamed or friable tissues may contain a dense network of friable capillaries may 
prove a challenge [1, 2, 7]. Junctional bleeding in trauma may be potentially cata-
strophic and its control may not be amenable to the above methods.
The use of pharmacological methods can be a useful adjunct to other methods in 
these circumstances [7]. These may include epinephrine, desmopressin, tranexamic 
acid, vitamin K, aminocaproic acid and others.
In some situations though, even the above methods are ineffective or impractical 
[15] and hence the development of topical hemostatic agents. These are a diverse 
group of agents of varying composition and mechanisms of action. They can be 
versatile in the sense that when blood loss is minimal, they can be used sparingly 
and when there is severe blood loss then more liberal application could be an option 
[2]. They may be applied directly to the bleeding site and prevent or reduce con-
tinuous and unrelenting bleeding intraoperatively and postoperatively [2] and their 
topical nature broadly avoids the systemic adverse effects associated with systemic 
hemostatic medications including thrombosis [8].
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4. Topical hemostasis
4.1 Concept of passive and active hemostasis
Topical hemostasis is defined as a process that acts locally to stop bleeding from 
damaged vessels [21]. Recent and continuing developments have focused on agents 
that can be used as adjuncts to control bleeding during surgical procedures and 
control residual problematic bleeding if conventional methods fail. Broadly speak-
ing, topical hemostats can be divided into three types [17, 20].
1. Passive—where the mechanism of action is to provide a physical scaffold 
around which platelets can aggregate. These act through contact activation and 
promote platelet aggregation so a clot can form. Examples include collagen, 
cellulose and gelatins.
2. Active—these have biological activity and their mechanism of action is ac-
tively influencing the clotting cascade to promote clot formation [17, 20]. These 
usually contain thrombin in one form or another [14].
3. Combined—combination of passive product with thrombin.
4.2 Passive hemostasis
4.2.1 Collagen-based products
Contact activation occurs between receptors on platelets and collagen, promot-
ing platelet aggregation [15, 17]. Preparation includes collagen sponges, pastes 
and powders [15, 17] and is obtained mainly from bovine sources [15], making it 
potentially immunogenic. In fact a 2–4% allergy in the total population to bovine 
collagen has been reported in the literature [22] (Table 1).
4.2.2 Cellulose-based products
The active ingredient in this product is oxidized regenerated cellulose (ORC). Its 
exact mechanism of action is poorly understood but contact activation is thought 
to play a part [15]. Often at reoperation, previously used ORC is visible, indicating 
reduced absorption and poor biodegradability, although this may be related to the 
amount used and the site of implantation [8]. For this reason, only the minimum 
Hemostatic agent Examples Manufacturer
Collagen-based products Avitene Davol/BD BARD
Helistat/Helitene Integra Lifesciences
Instat/Ultrafoam Ethicon. Johnson & Johnson
Oxidized cellulose Surgicel Fibrillar Ethicon, Johnson & Johnson
Surgicel Nu-Knit Ethicon, Johnson & Johnson
Gelatin-based products Gelfoam Pharmacia Corp, Pfizer
Surgifoam Johnson & Johnson
Polysaccharide spheres Arista AH BD BARD
Table 1. 
Passive hemostats.
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possible amount to be used is indicated and it is recommended that the product be 
removed once hemostasis is achieved and before definitive closure [6, 8].
4.2.3 Gelatin-based products
Their mechanism of action involves swelling while in contact with blood, pro-
viding a tamponade effect in confined spaces and restoring blood flow, and thereby 
producing a stable scaffold around which clots can form [17]. This does make it suit-
able for irregular wounds [6] and confined spaces [17]. However, it tends to stick 
to instruments when soaked with blood, making it difficult to handle and does not 
form a tight bond with the bleeding surface and can hence easily be dislodged [17].
4.3 Active hemostasis
Active agents have biological activity and actively participate in the coagulation 
cascade to induce clot formation at the site of bleeding [20]. They include thrombin, 
which comes into play in the last stages of the clotting cascade, converting circulat-
ing fibrinogen to a fibrin clot [17, 23]. Hence a significant advantage of thrombin 
is that its action is less susceptible to coagulopathies caused by clotting factor or 
platelet dysfunction [17]. Its activity constitutes the final steps in the clotting 
cascade and therefore it bypasses the initial steps in the cascade. Therefore, other 
aspects of the clotting cascade can be dysfunctional without significantly impairing 
the local hemostatic activity of thrombin [20].
Thrombin-based products are therefore excellent adjuncts in the presence of 
congenital and acquired coagulation and platelet disorders and in the presence of 
pharmacological and antiplatelet agents that are increasingly being used in the gen-
eral population [5, 17]. Circulating fibrinogen is necessary for hemostasis to occur 
by active agents as thrombin converts it into insoluble fibrin that forms part of the 
clot. Therefore in rare cases of fibrinogen deficiency, clotting by thrombin-based 
products is impaired [17, 23].
5. Combination agents
5.1 Fibrin sealants
These accomplish their action by bypassing the coagulation cascade to the final 
steps and converting fibrinogen to fibrin [24]. A fibrin precursor and thrombin 
stored in two separate adjacent syringes (dual syringe kit) with a single lumen 
enables delivery and mixing of these agents in the lumen and onto the surgical 
site, causing thrombin to cleave the fibrin precursor, resulting in fibrin monomers 
that polymerize at the site into a soluble mesh stabilized into a stable clot by factor 
XIII at the tissue surface [25]. Previously, bovine thrombin was used, which has 
recently been replaced by human thrombin [26] and more recently autologous 
human thrombin. Autologous fibrin sealants overcome the risk of allogeneic blood 
products, for example one is a patient-derived fibrin sealant utilizing the patient’s 
own blood as a source of fibrinogen and prothrombin and mixing it with an alkaline 
buffer solution to lower the pH, activating endogenous prothrombin [24] (Table 2).
5.2 Platelet gels
These are a combination of thrombin, calcium and platelet-rich plasma, usu-
ally obtained from autologous sources using centrifugation systems that produce 
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platelet-rich plasma. Platelets provide growth factors to stimulate wound healing 
and contribute to the strength of the clot [27].
These systems however rely on an intact coagulation system and may not be 
as effective in patients on antiplatelet or anticoagulant medications [27]. Also the 
extraction systems are expensive and there is a risk of contamination.
5.3 Advantages of active and combined products over passive hemostats
In addition to not requiring normal clotting mechanisms to work as mentioned 
before, active hemostats may offer other advantages. With many passive hemo-
static agents, degeneration and reabsorption are a problem. This necessitates their 
removal from the surgical site prior to closure. With thrombin, this is not the case as 
degeneration and resorption of the resulting fibrin clot is achieved as part of wound 
healing [1, 8]. Thrombin and combination products also have a rapid onset of action 
with hemostasis being achieved within 10 min in most patients [7, 17, 28, 29]. Studies 
have shown that combining an active hemostat within a hemostatic product acceler-
ates clotting. In a comparison of collagen-based products at different bleeding sites 
after surgical tumor resection, the combination of a collagen-thrombin product 
(n = 23) achieved complete hemostasis three times faster than the collagen sponge 
alone (n = 30). The median time to hemostasis was 78 seconds versus 243 seconds 
respectively (p < 0.001) [30]. Furthermore, approximately 80% achieved complete 
hemostasis within 2 min with an active topical hemostatic agent compared with only 
one-third of patients receiving a passive topical hemostatic agent [31]. Active hemo-
stats are also very versatile and can come in various forms. These include sprays that 
can be advantageous in covering large bleeding surfaces quickly without the need 
for tamponade [31], and the concentration of thrombin in the formulation can also 
be varied depending on the severity and type of bleeding. Surgeons can use them in 
multiple ways during a single procedure due to their flexibility and range of delivery 
options [20]. Although bovine sources of thrombin may induce antibodies in hosts, 
this has not manifest itself as a major problem in the clinical setting [1, 32].
5.4 Hemostasis in the trauma setting
It has been shown that the terrible triad of hypothermia, coagulopathy and 
acidosis are associated with increased mortality in multiple trauma patients and 
that infection and multiple organ failure are other potential complications arising 
from severe blood loss [33, 34]. About a quarter of patients presenting to trauma 
centers have an established coagulopathy secondary to hemorrhage [35] with atten-
dant risks of significant complications. Multiple defects in hemostasis can occur in 
Biosurgical Examples Manufacturer
Liquid fibrin adhesives Tiseel Baxter
Evicel Ethicon, Johnson & Johnson
Crosseal Ethicon, Johnson & Johnson
Floseal Baxter
Fibrin patches Tachosil Takeda
Platelet gels Vitagel Orthovita
Glutaraldehyde cross-linked albumin BioGlue Cryolife
Table 2. 
Sealants and adhesives.
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combat injuries and as such, conventional methods of hemostasis may not be pos-
sible. Time is of the essence in these situations and non-transfusional approaches to 
hemostasis and the use of biosurgicals may be indicated [36–39].
The combat setting has proved a challenging environment in many different 
ways in terms of management of hemorrhage. The tissue available for controlling 
life-threatening hemorrhage may be limited, the wound severity and the possibil-
ity of multiple injuries make the situation uniquely challenging [40]. Most combat 
injuries are penetrating in nature and a large proportion are limb wounds. Mortality 
from hemorrhage from these kinds of wounds is potentially preventable [36, 41, 42].
In the combat setting, the three principal sites of lethal hemorrhage are truncal 
(67%), junctional (19%) and extremity (14%). A report from the National Trauma 
Database suggests that the mortality from isolated lower limb extremity trauma 
with arterial injury is 2.8% with a 6.6% amputation rate [38]. Tourniquets can be 
used for these isolated injuries and their use in the military and civilian setting is 
supported by the Hartford consensus [39] and by the American College of Surgeons 
Committee on Trauma [38].
Junctional injuries (neck, axilla, groin and perineum) form a significant propor-
tion of trauma in a combat setting and may damage the large vascular structures. 
These types of injuries are difficult to compress and are not amenable to tourniquet 
control [43, 44]. Topical hemostatic agents that have been developed in the last 
two decades [36, 45] can play a vital role in controlling severe bleeding in these 
situations and increase survival [33, 46] and have thus been listed as optional basic 
equipment for ambulances [39]. In addition, in a combat setting, more complex 
types of wound patterns are encountered than in a civilian setting, including blast 
injuries, which may be more amenable to topical hemostasis.
5.5 Characteristics of the ideal trauma hemostatic agent
In 2003, USAIR [47] introduced guidelines of what should constitute the perfect 
hemostatic agent for use in the prehospital and battlefield settings [33, 41, 47–49] 
that included the following: being able to stop large vessel and arterial bleeding 
within 2 min of application, ability to be delivered through a pool of blood when 
applied, ready to use with no need for on-site preparation, simple enough to use 
by the wounded victim or a paramedic with minimal training, light weight and 
durable with a minimum 2-year shelf life in extreme environmental conditions, 
safe to use with no risk of injury to tissues or transmission of infection and inex-
pensive [41, 45, 50, 51]. In addition, hemostatic dressings need to be conformable 
and flexible enough due to the irregular shape, depth and wound configurations 
caused by modern explosive devices [40, 48].
6. Types of hemostatic agents
6.1 Mechanical hemostats
These include gelatin [52], oxidized cellulose [53] and collagen and plant-derived 
polysaccharide spheres [54]. These agents are not biologically active and rely on the 
patients’ endogenous fibrin production for hemostasis. They provide a scaffold for 
platelet activation and aggregation, absorbing fluid several times their own weight to 
form a matrix at the site of hemorrhage, activating the extrinsic coagulation pathway 
and allowing clotting to occur. This makes them suitable only for patients in whom 
the coagulation system is intact [55, 56]. In fact in the absence of some coagulation 
factors, these agents may not be effective [53, 56]. They can be used as first line due 
7Hemostasis and Biosurgicals in Trauma and Orthopedic Surgery
DOI: http://dx.doi.org/10.5772/intechopen.92805
to their ready availability and favorable cost-effectiveness, mostly as adjuncts with 
direct pressure at bleeding sites to control minimal residual hemorrhage [56].
6.1.1 Bovine collagen
These agents act by forming a physical matrix that stimulates platelet aggrega-
tion and degranulation to release factors that encourage clot formation [55].
6.1.2 Oxidized cellulose
Cellulose is a homopolysaccharide made by polymerization of glucopyranose 
molecules through glucosidic bonds. Surgical oxidized cellulose is either regener-
ated where organized fibers are formed prior to oxidation (regenerated ORC), or 
non-regenerated, with unorganized fibers prior to oxidation [55]. ORC conforms 
more rapidly to the surrounding environment. Surgical oxidized cellulose offers 
several favorable properties in hemostasis including bactericidal activity, good 
biocompatibility and ease of use [55]. It is usually resorbed but can take anywhere 
between 2 and 6 weeks depending on the amount used, the degree of saturation 
with blood and the tissue bed. The excess material may also cause foreign body 
reactions and granuloma formation without biodegradation and complicate radio-
logical and clinical diagnoses of abscess, residual or recurrent tumor and granuloma 
[55, 57, 58]. For this reason, the minimal effective amount should be used and excess 
material removed prior to definitive closure. In addition, these products should not 
be used or left in place close to nerves, ureters, intestinal and vascular structures 
due to the risk of local inflammatory reactions and ischemia [55].
6.1.3 Gelatin-based products
These can be used in combination with active agents such as thrombin in adhesives, 
or in a stand-alone manner. They are usually of bovine or porcine origin and act at the 
terminal stages of clotting to facilitate fibrin clot formation and are highly absorptive, 
forming a mechanical matrix for the clot to adhere to [55, 59]. They are quite versatile 
and available as sponges, powders or granules and are usually completely resorbed 
in 4–6 weeks [59]. It is important to use the minimum amount necessary to achieve 
hemostasis and to remove excess because part of the mechanism of action is swelling 
to cause a tamponade effect and this could potentially cause compression and necrosis 
in surrounding tissues if packed in tight spaces. This is particularly important around 
neural tissue and in bony spaces [59]. They are also useful in irregular wounds and 
surgical cavities as they can expand and fill these irregular spaces.
6.1.4 Plant-based hemostatic agents
Mucoporous polysaccharide hemispheres are among a relatively new class of 
hemostatic agents derived from plant starch. Their mechanism of action includes 
absorbing water and the low-molecular weight components of blood, hence concen-
trating platelets and clotting factors in the vicinity, thereby enhancing local clotting 
processes [58, 60]. They have been used safely in cardiothoracic and neurospinal 
surgery.
6.2 Fibrin sealants/adhesives
These are active formulations containing mostly two agents—human purified 
fibrinogen and thrombin. They may also have added other compounds such as 
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factor XIII, fibronectin and antifibrinolytics such as aprotinin used previously and 
tranexamic acid currently [61]. However, formulations without tranexamic acid 
or aprotinin are available to avoid hypersensitivity associated with aprotinin and 
neurotoxicity associated with tranexamic acid [62, 63] (Table 2).
These products are available in liquid or low-viscosity forms (fibrin glues) or as 
part of stiff collagen fleece (fibrin patches) [55]. Once applied, their mechanism of 
action is cleavage of fibrinogen to fibrin monomers by thrombin, which also activates 
factor XIII and the complex fibrin matrix forms the clot [55]. Calcium is required in 
both these steps and then the clot is eventually resorbed via the fibrinolytic pathway 
[25]. Generally, they connect atraumatically to tissues and form a barrier to leakage 
and bleeding through covalent polymerization between themselves and adjacent 
tissue [55]. Chiara et al. set out the properties of an sealant as being strong, rapid to 
adhere, flexible, sterile, without toxicity, biologically inert, biocompatible and able 
to be used in relatively wet environments with low thrombogenicity [55].
7. True sealants and bioglues
True sealants are of two types: synthetic (PEG-based or cyanoacrylates) [53, 60, 
64–67] or semisynthetic glutaraldehyde [68] (Table 2).
True sealants are cross-linking sealants that polymerize through nonenzymatic 
reactions, free of the need for the presence of blood or coagulation factors although 
some do have some coagulation factors within them. Both can be used to control 
residual ooze [53, 67].
PEG sealants are composed of polyethylene glycol and come in both flowing form 
as well as pads or fleeces. They should be avoided in kidney disease due to the renal 
clearance of polyethylene glycol and may contain allergenic components such as 
human albumin that can also lead to the theoretical risk of disease transmission [55].
Cyanoacrylates are products generally used for skin closure or lacerations in 
areas of low skin tension, for example scalp wounds. They are synthetic sealants 
that rapidly polymerize with water acting as the catalyst. There are two formula-
tions: octyl-2-cyanocrylate and N-Butyl-2-cyanoacrylate. In a systematic review 
looking at octyl-2-cyanoacrylate, there were no differences in infections, wound 
dehiscence or cosmetic appearance when compared with other methods of closure 
[65]. Polymerization generates heat and therefore the amount used should be just 
enough and should certainly be avoided in delicate areas such as the spinal canal and 
neural tissue [55, 65]. Below the skin, a foreign body reaction may occur [65] and 
intravascular use is contraindicated due to the risk of systemic embolization [55].
Semisynthetic sealants otherwise known as bioglues are compounds of semi-
synthetic glutaraldehyde—bovine albumin-based sealant. Proteins on the surface 
of bleeding human tissue link with those of bovine albumin in the bioglue, causing 
a sealant effect [55]. Within synthetic graft materials, bioglue permeates interstices 
within the graft matrix [69], making it suitable for sealing anastomotic sites and 
decreasing postop bleeding [70].
7.1 Liquid fibrin adhesives
These can be used as an adjunct to surgical hemostasis to improve residual 
moderate bleeding [55]. They are usually applied by double syringe systems. Each 
component is located in a separate section of the syringe, which then combine in 
a single lumen. They subsequently are applied using a blunt needle or spray tips in 
cases of large bleeding surface areas to the bleeding surgical site [25, 61]. Since the 
components bypass the initial steps in the extrinsic coagulation pathway, they can 
9Hemostasis and Biosurgicals in Trauma and Orthopedic Surgery
DOI: http://dx.doi.org/10.5772/intechopen.92805
be used in achieving hemostasis in patients with congenital or acquired bleeding 
disorders such as hemophilia and patients on anticoagulants or antiplatelet medica-
tions [25, 62, 71] (Table 2).
They do have some drawbacks including the risk of thrombosis if injected 
intravascularly, hypotension and death and the risk of air embolization with the use 
of gas-driven sprayers [55]. In addition, the cost of sealants is significant and hence 
they are not recommended for use except in particular situations where indicated, 
for example in those with coagulation disorders [61]. One cost-effectiveness analysis 
done in the United Kingdom in patients undergoing total knee replacement on 
Quixil, one of the commercial brands, in addition to conventional hemostatic agents 
estimated that the use of a 5-ml dose of Quixil in addition to conventional hemostatic 
methods was cost saving in comparison to conventional methods alone. But the use 
of a 10-ml dose increased the cost substantially and they recommended that liquid 
fibrin adhesives only be used in selected cases [25]. They have however been found 
to be effective. Echave et al. [59] carried out a systematic review of 27 studies on the 
effectiveness of human gelatin-thrombin matrix sealant in different surgical fields 
including orthopedics. All 27 studies demonstrated that this sealant was associated 
with a significantly higher rate of successful hemostasis, and a shorter time to achieve 
it (p < 0.001) in comparison to other alternatives when conventional methods failed.
7.2 Fibrin patches
These products are also available as patches, for example Tachosil. They may 
have slightly different components but all of them have essentially the same mecha-
nism of action, offering mechanical support with either collagen, oxidized cellu-
lose/polyglactin 910 matrix, binding coagulation factors, allowing better adherence 
to bleeding tissue even in the presence of brisk bleeding, preventing the so-called 
“streaming effect” observed with fluid adhesives [72–74]. Tachosil is a ready-to-use 
fixed combination of equine collagen patch on one side and coated with coagulation 
factors, human fibrinogen and human thrombin on the other side [55]. Fibrin-pad 
and PGA-felt are absorbable hemostats composed of polyglactin 910, oxidized 
regenerated cellulose, thrombin and fibrinogen shown to be effective in a variety 
of tissue types [25, 72] and can rapidly achieve hemostasis in brisk bleeding in the 
retroperitoneum and pelvis, compared with the standard of care [72, 73] (Table 2).
8. Hemostasis in major trauma
8.1 Hemostatic dressings
Junctional hemorrhage is a significant problem in major trauma especially on the 
battlefield and often conventional methods such as tourniquets are ineffective [55]. 
In this respect, science has led to the development of products that are effective 
options in these circumstances and they can be divided into factor concentrators 
[75], procoagulants [76] and mucoadhesives [77] (Table 3).
8.1.1 Factor concentrators
These are compounds of either zeolite (microporous crystalline aluminum 
silicate) or smectite (a nonmetallic clay mineral sodium, calcium and aluminum 
silicate). Examples include QuikClot (Z-Medica LLC, CT,USA) and QuikClot 
ACS (advanced clotting sponge), Traumadex (Medafor Inc., MN, USA) and self-
expanding hemostatic polymer (SEHP) [35]. As the group name suggests these 
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agents rapidly absorb the fluid content of blood. The resulting effect is an increase 
in relative concentration of its cellular and protein content and therefore clot forma-
tion. Water molecules are held in its pores by hydrogen bonds and this results in a 
relative local increase in concentration of platelets and clotting factors [35]. The first 
generation of QuikClot was designed as granules that were poured onto the bleeding 
wound. A high efficiency rate of 92% was demonstrated in a series of 103 patients in 
the military and civilian setting. There were eight patients in which hemorrhage was 
not effectively controlled with QC in coagulopathic patients where it was used as a 
last resort [75]. There were also some side effects of QC including intense exother-
mic reaction and scar formation from foreign body reaction [75]. Animal and early 
human studies on QC revealed thermal injury, poor biodegradability and foreign 
body reactions as the main drawbacks of QC [78–80]. In fact temperature generated 
by QuikClot in contact with aqueous components of blood at bleeding wounds has 
been measured to reach and average of 61°C with a potential rise to 76°C [78].
QuikClot has been compared to other hemostatic agents including HemCon 
(HemCon Medical Technologies Inc., OR, USA) in a military setting in multiple 
patients injured after explosions and gunshot wounds [81]. In this study, QC was 
effective but thermal injury was an issue. This has also been investigated in other 
studies by McMannus et al. [82] in the combat setting and evidence suggests that 
the greater the amount of blood and the more the QC applied, the greater is the risk 
of thermal injury. Thus currently it is only recommended for external use and the 
minimum amount required to achieve effective hemostasis is recommended.
QuikClot ACS is a newer generation of product made by larger zeolite beads pack-
aged into mesh bags. This makes it easier to pack into cavities and irregular wounds 
often found on the battlefield and at junctional sites of hemorrhage and in cavities 
[55] and is claimed to produce much less of an exothermic reaction [75, 78] although 
there is a lack of studies with sufficient numbers to confirm this unequivocally [41].
Self-expanding hemostatic polymer (SEHP) is a dual action factor concentra-
tor. Its mechanism of action results from its extremely potent absorptive capacity 
following absorption of the fluid component of blood and its ability to expand to 
conform to large irregular cavities and spaces, exerting a tamponade effect [35]. The 
other action is the effect of the polymer absorbing the liquid phase of blood into 
its matrix, thereby leading to a relative increase in concentration of platelets and 
coagulation factors at the site of bleeding, thereby promoting clotting [83, 84].
Woundstat is a compound of smectite granules that come in granular form. Its 
mechanism of action is absorption of the aqueous phase of blood, forming a clay 
substance that adheres to bleeding tissue and acts as a sealant and also concentrates 
clotting factors and blood cells locally, contributing to hemostasis. Granules are 
negatively charged and activate the intrinsic pathway as well [85–87].
Biosurgical Examples Manufacturer
Zeolite dressings QuikClot & QuikClot ACS Z-Medica
Smectite dressings WoundStat TraumaCure Inc.
Kaolin dressings QuikClot Combat Gauze Z-Medica
Rapid Deployment Hemostat Marine Polymer Technologies
Celox Med Trade Products, UK
Trauma Stat OreMedix
Fibrin dressings Dry fibrin sealant dressing (DFSD) American Red Cross
Table 3. 
Hemostatic dressings.
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8.1.2 Mucoadhesive agents
These are products where the basic component is chitosan, which is a polymer 
derived from crustacean chitin. It is a complex biodegradable carbohydrate [55]. 
The mechanism of action appears to be related to highly positively charged chitosan 
interacting electronically with negatively charged cell membranes of erythrocytes. 
The product adheres strongly to tissues and seals bleeding wounds [77, 88, 89]. 
Examples include HemCon (HemCon Med Tech, Portland, OR) and Celox 
(Med. Trade Products, UK).
Celox is a chitosan-based adhesive, which is biodegradable and causes absorp-
tion of the aqueous phase and the advancement of red blood cell bonding. The 
positively charged Celox binds negatively charged red blood cells independently 
of the body’s clotting system, resulting in clot formation without the exothermic 
reaction associated with certain factor concentrators like QuikClot [35]. Its action 
is independent of the body’s clotting system, a property that makes it useful in 
patients requiring antiplatelet or anticoagulant medications or in the presence of 
coagulopathy and its local action means that it is not associated with distant clot 
formation. It is also reported to be very versatile, being available in granular and 
bandage forms and easy to remove from the wound after its clot formation activity 
is complete [49, 90–92]. HemCon, however, does have a hard consistency and is 
made in a square shape. Therefore, it works best on flat bleeding surfaces rather 
than deep irregular wounds [79, 83]. Wedmore et al. [77] looked at a series of 
patients with prehospital combative injuries where chitosan-based products had 
been used externally in chest, groin, buttock and abdominal wounds in 25 patients, 
35 extremity wounds and neck and facial wounds in 4 cases. In about two-thirds of 
cases, the chitosan dressings were used following failure of hemostasis using only 
gauze with 100% success. In 97% of cases, bleeding stopped or hemostasis was 
improved, with failure only occurring in two cases attributed to blind stuffing of 
bandages into large cavitational injuries [77].
Trauma Stat is another chitosan-based derivative that was developed in col-
laboration with the United States Army, in which the mechanism of action involves 
positive charges in the amine groups on the chitosan molecule interacting with 
negative charges on the red blood cell membranes and in addition the adsorption of 
chitosan for fibrinogen and plasma proteins [79, 93].
Te Grotenhuis carried out a study of 66 patients in which conventional treatment 
with gauze and compression failed to control excessive bleeding or where conven-
tional treatment was unlikely to achieve hemostasis. Complete cessation of hemor-
rhage including arterial hemorrhage occurred in 70% using the HemCon ChitoGauze, 
and reduction in hemorrhage occurred in 20% of patients despite 21 patients being on 
anticoagulants or having a clotting disorder and no adverse events occurred [88].
Due to the fact that chitosan is derived from crustaceans, there is a theoretical 
risk of allergenic reactions in patients allergic to shellfish. However in a study of 19 
patients who had a positive IgE test to shellfish, none of the patients demonstrated 
a positive skin prick test to chitosan powder or expressed a reaction to HemCon 
bandage during serial bandage challenges, indicating favorable but not completely 
risk-free use of these products [94].
Chitosan-based dressings are also easy to remove after hemostasis has been 
achieved [41] and are known to have some antimicrobial properties [41, 95].
8.1.3 Procoagulants
Their mechanism of action is mainly to deliver factors that promote coagulation 
into the bleeding wound. Examples are dry fibrin sealant dressing (DFSD) and 
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QuikClot Combat Gauze (QCG) [70, 96, 97]. QCG is a surgical gauze coated with 
kaolin. On contact with injured endothelium, kaolin activates the extrinsic pathway, 
enhancing coagulation and promoting hemostasis. It is not degradable and needs to 
be removed from the wound following achievement of hemostasis [76].
Kaolin-based products have been used in a military setting and have demon-
strated good results in both junctional and non-junctional hemorrhage [76]. In 
the above study, Shina et al. retrospectively reviewed 133 kaolin-based dressings 
applied to 122 military patients. 27% were for junctional hemorrhage with a success 
rate of 88% while the rest were extremity trauma where the success rate was 92%.
8.2 Problems with hemostatic agents
In addition to problems specific to certain types of hemostatic agents, there are 
also general drawbacks.
The hemostats that contain biological agents, usually the active hemostats, can be 
associated with the risk of disease transmission. For example, DFSD has the theo-
retical risk of viral disease transmission and hence has not achieved FDA approval.
Some agents have handling characteristics that are beneficial in certain situ-
ations. For example agents that have a granular nature can be used for complex 
irregular wounds with multiple bleeding points. However, the handling charac-
teristics are difficult and they are difficult to apply in combat situations [89]. In 
addition, many agents are nonabsorbable and need to be removed after hemostasis 
is achieved. This may be difficult with some agents and require multiple washouts. 
Granular agents also have the potential to enter the vascular system and occlude the 
distal parts of vessels, causing endothelial injury and intravascular coagulation [41]. 
This has been demonstrated by Kheirabadi et al. [89] in their study, and for these 
reasons a bandage/gauze form of hemostatic agent is preferable as being safer for 
hemorrhage control, avoiding intravascular complications [38].
8.3 Tranexamic acid in trauma
Any chapter on hemostasis in trauma and orthopedics is incomplete without the 
mention of tranexamic acid. This drug has been shown to be effective in reducing 
mortality due to bleeding in both the military and civilian setting.
The CRASH-2 (Clinical Randomization of an Antibrinolytic in Severe 
Hemorrhage-2) trial was a multicenter trial involving 40 centers looking at 20,211 
adult trauma patients with significant bleeding who were randomized to two arms. 
One arm received TA within the first 3 hours of trauma and the other received pla-
cebo. The study demonstrated a reduction in mortality risk due to any cause from 
14.5% compared with 16% in the placebo group (p < 0.001), with no increase in 
vasoocclusive events such as pulmonary embolism or myocardial infarction (0.3% 
versus 0.5% p-0.096) [98].
The MATTER (Military Application of Tranexamic Acid in Trauma) study 
looked at 896 patients with severe combat injuries and demonstrated a 6.5% absolute 
risk reduction in mortality in these patients with the use of tranexamic acid [99].
Both these studies have recommended incorporation of intravenous tranexamic 
acid into clinical practice [24].
8.4 Hemostasis in arthroplasty surgery
Joint replacements are major procedures in elective orthopedics and can be asso-
ciated with significant blood loss and increased transfusion requirements if appro-
priate steps are not taken to mitigate against this. In addition to the conventional 
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methods of blood management including preoperative optimization, tourniquets if 
appropriate, intraoperative techniques such as cell saver and cauterization, topical 
and pharmacological hemostats and biosurgicals may offer some excellent solutions 
to reduce the transfusion requirements and achieve hemostasis.
A few studies have looked at human-derived fibrin sealants in total knee replace-
ment [100–102]. A multicenter randomized control trial looking at 58 patients who 
underwent total knee replacement demonstrated a reduced postoperative blood 
loss, reduced postoperative decrease in hemoglobin and calculated blood loss in 
patients in whom fibrin sealant was used compared with that in the standard group 
(20% compared with the standard 83% p = 0.004) [100]. Another study that 
showed benefit was done by Dhillon et al. [25]. Results from other studies have been 
equivocal and have not demonstrated any clear difference.
In total hip arthroplasty, the use of fibrin sealants has been associated with 
reducing blood loss but inconsistent results have been demonstrated with regard to 
reduction in postoperative transfusion requirements [24, 103–105].
Multiple studies have looked at platelet gels in arthroplasty surgery. The evi-
dence has been inconsistent in many. One randomized control trial looking at 100 
total knee replacements did demonstrate significantly lower transfusion require-
ments in patients in whom platelet gels were used [106].
Desmopressin is a synthetic analog of anti-diuretic hormone. Its mechanism 
of action is to increase the levels of factor VIII and Von Willebrand factor, thereby 
enhancing primary hemostasis and platelet aggregation and adherence. This makes it 
suitable as a blood management strategy in patients with platelet dysfunction or other 
clotting disorders such as Von Willebrand’s disease and hemophilia A [107, 108]. It has 
also been used in healthy individuals for reducing postoperative bleeding in total hip 
and knee replacement surgery [109]. Six randomized placebo-controlled trials address-
ing the use of desmopressin in total hip and knee arthroplasty have been undertaken 
[110–115]; however, evidence suggests that desmopressin is not significantly effective 
in reducing blood loss or transfusion requirements in these patients [24].
There are a number of good-quality randomized control trials that support the 
use of tranexamic acid in reducing blood loss and transfusion requirements in both 
knee and hip arthroplasty surgery [24]. There is however considerable amount of 
heterogeneity between the trials with regard to methods of delivery including single 
intravenous bolus dose, repeated boluses, prolonged infusion or intraarticular 
injection [116], and also differing dosing regimes [117]. In total knee arthroplasty, 
it has been shown that one intraoperative dose is sufficiently effective in reducing 
transfusion requirements and postoperative bleeding [118]. With the theoretical 
risk of intravascular thrombosis, intraarticular injection of tranexamic acid was 
investigated and compared to placebo and the studies showed reduction in blood 
loss but no reduction in transfusion rates [101, 119, 120]. Only one RCT by Seo et al. 
[121] showed a reduction in transfusion requirements with intraarticular (20%) 
rather than intravenous (34%) or placebo (94%). The evidence in total hip replace-
ment with regard to intraarticular tranexamic acid is less convincing than in knee 
arthroplasty and more studies are needed.
With regard to aminocaproic acid, three RCTs did demonstrate benefit in hip 
and knee replacement surgery in terms of reducing blood loss in comparison with 
placebo. However, with regard to reducing transfusion requirements the evidence is 
much less convincing [24, 122–124].
8.5 Hemostasis and biosurgicals in spine surgery
Spine surgery presents a few unique challenges that limit the products that can 
be used for hemostasis in these situations. One of them is the friability of neural 
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tissue and secondly the fact that the spinal cord and nerve roots are enclosed in 
rigid bony spaces that limit the kinds of hemostats that can be used due to the 
potential of swelling and compression of neural tissue in a rigid space. In addition, 
there is the potential for neurotoxicity with certain agents.
Cerebrospinal fluid leaks are a common source of postoperative morbidity in 
patients who have undergone spinal surgery. The morbidity burden includes severe 
postural headaches, vomiting, dizziness, photophobia, tinnitus, pseudomenin-
goceles and the risk of meningitis. It is therefore important that when dural tears 
occur or when an iatrogenic durotomy is created a water tight repair is essential. 
PEG hydrogel sealant has been found to be a safe effective way to augment dural 
closure and prevent these complications. A prospective study by Kim et al. [66] 
demonstrated that augmentation of standard dural closure techniques with this 
sealant in patients had significantly higher rates of watertight closure than with 
controls (100% and 64.3% respectively), without statistical differences in cerebro-
spinal fluid leaks, infections or wound healing. Complications due to swelling of 
polyethylene glycol and nerve compression were not demonstrated in this study but 
this remains a possibility. This led to the development of low-swell PEG hydrogel 
sealant (Duraseal) [55] and has been found to be safe and effective in a 3-to-1 ran-
domized single-blind multicenter trial in which 100% of patients who had this low-
swell formulation achieved watertight dural closure. Another study has also shown 
that BioGlue (semisynthetic glutaraldehyde-bovine albumin sealant) is safe and 
cost-effective in proximity to neurological structures despite previous concerns. 
Miscusi et al. [125] demonstrated a watertight dural closure in 23 patients requiring 
dural repair, with no incidence of neurological or infection related complications.
Collagen and gelatin-based products can be used to achieve hemostasis in spinal 
surgery. Xu et al. [64] carried out a study on 92 patients undergoing spinal fusion 
surgery and concluded that collagen-based products are superior to gelatin-based 
products in achieving hemostasis in spine surgery, with lower blood loss and 
postoperative drain volume.
Oxidized regenerated cellulose has been used for hemostasis in spine surgery. 
However when used around or in foramina with rigid bony walls, the swelling of 
small portions of the cellulose material may lead to significant mass effect and 
neural compression 1 day after surgery as demonstrated by Menovsky et al. [126] 
and may lead to rapid neurological deterioration. Therefore this material should be 
removed after hemostasis has been achieved prior to closure.
As mentioned before, liquid fibrin sealants can be used in spine surgery for 
hemostasis, but those containing tranexamic acid may be associated with neurotox-
icity and should not be used if CSF leak or dural tear is present [55].
9. Conclusions and future perspectives
Topical hemostats and biosurgicals are a diverse group of compounds that have 
been developed and can be used in different situations as part of a comprehensive 
blood management program to limit the amount of blood loss. Trauma and ortho-
pedics as a specialty also presents some unique challenges, with operations having 
significant blood loss and in trauma, junctional injuries on the battlefield with hem-
orrhage that is hard to control by conventional means. In addition, patients may be 
complex and frequently have platelet or coagulation disorders that preclude the use 
of certain classes of hemostatic agents. As mentioned before, these compounds are 
diverse, with different mechanisms of actions and indications, both in an elective 
and an emergency trauma setting. A comprehensive knowledge of these products is 
essential in modern-day trauma and orthopedic practice.
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Despite recent developments, the perfect hemostatic or biosurgical agent still 
remains elusive and each of these products has their own drawbacks, side effects 
and unique indications and future research will hopefully continue to improve 
on these.
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